---
reference_id: "PMID:24725239"
title: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
authors:
- Afdhal N
- Zeuzem S
- Kwo P
- Chojkier M
- Gitlin N
- Puoti M
- Romero-Gomez M
- Zarski JP
- Agarwal K
- Buggisch P
- Foster GR
- Bräu N
- Buti M
- Jacobson IM
- Subramanian GM
- Ding X
- Mo H
- Yang JC
- Pang PS
- Symonds WT
- McHutchison JG
- Muir AJ
- Mangia A
- Marcellin P
- ION-1 Investigators
journal: N Engl J Med
year: '2014'
doi: 10.1056/NEJMoa1402454
content_type: abstract_only
---

# Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
**Authors:** Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators
**Journal:** N Engl J Med (2014)
**DOI:** [10.1056/NEJMoa1402454](https://doi.org/10.1056/NEJMoa1402454)

## Content

1. N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub
2014  Apr 11.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Afdhal N(1), Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, 
Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, 
Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir 
AJ, Mangia A, Marcellin P; ION-1 Investigators.

Collaborators: Bourlière M, Bronowicki JP, Hézode C, Marcellin P, Ratziu V, 
Serfaty L, Zarski JP, Berg T, Buggisch P, Galle P, Gerken G, Goeser T, Lohse A, 
Mauss S, Thimme R, Wedemeyer H, Zeuzem S, Alberti A, Andreone P, Angelico M, 
Colombo M, Craxì A, Mangia A, Puoti M, Rizzetto M, Rodriguez-Torres M, Andrade 
R, Buti M, Crespo J, Forns X, García-Samaniego J, Romero-Gomez M, Agarwal K, 
Brown A, Cramp M, Dusheiko G, Foster G, Mutimer D, Ustianowski A, Afdhal N, 
Albers C, Arora S, Beavers K, Bennett M, Bernstein D, Bräu N, Brown R Jr, 
Chojkier M, Chung R, Cooper J, Davis M, Di Bisceglie A, Dretler R, Elion R, 
Everson G, Flamm S, Freilich B, Fried M, Galati J, Ghalib R, Gitlin N, Gordon S, 
Han SH, Hawkins T, Herring R, Hinestrosa F, Jacobson I, Jeffers L, Kowdley K, 
Kugelmas M, Kwo P, Lawitz E, Lee W, Morgan T, Nahass R, Nelson D, Nguyen M, 
Patel K, Pockros P, Poleynard G, Poterucha J, Poulos J, Pound D, Pruitt R, 
Ravendhran N, Reddy K, Reindollar R, Rossaro L, Ruane P, Rustgi V, Ryan M, Saag 
M, Schiff E, Sheikh A, Shiffman M, Smith C, Sulkowski M, Workowski K, Younes Z.

Author information:
(1)The authors' affiliations are listed in the Appendix.

Comment in
    Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):329. doi: 
10.1038/nrgastro.2014.64.

BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the 
nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir 
resulted in high rates of sustained virologic response among previously 
untreated patients with hepatitis C virus (HCV) genotype 1 infection.
METHODS: We conducted a phase 3, open-label study involving previously untreated 
patients with chronic HCV genotype 1 infection. Patients were randomly assigned 
in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose 
combination tablet once daily for 12 weeks, ledipasvir-sofosbuvir plus ribavirin 
for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus 
ribavirin for 24 weeks. The primary end point was a sustained virologic response 
at 12 weeks after the end of therapy.
RESULTS: Of the 865 patients who underwent randomization and were treated, 16% 
had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection. The rates 
of sustained virologic response were 99% (95% confidence interval [CI], 96 to 
100) in the group that received 12 weeks of ledipasvir-sofosbuvir; 97% (95% CI, 
94 to 99) in the group that received 12 weeks of ledipasvir-sofosbuvir plus 
ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 weeks of 
ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 
weeks of ledipasvir-sofosbuvir plus ribavirin. No patient in either 12-week 
group discontinued ledipasvir-sofosbuvir owing to an adverse event. The most 
common adverse events were fatigue, headache, insomnia, and nausea.
CONCLUSIONS: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 
or 24 weeks was highly effective in previously untreated patients with HCV 
genotype 1 infection. (Funded by Gilead Sciences; ION-1 ClinicalTrials.gov 
number NCT01701401.).

DOI: 10.1056/NEJMoa1402454
PMID: 24725239 [Indexed for MEDLINE]